Nanobiotix S.A. (NBTX) Stock Forecast
NBTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.60 / 5 from 5 analysts
- Price target
- $54.03 average of analyst targets
- Upside to target
- +153.7% from the latest close
- Next earnings
- —
- 52-week range
- $15.08 – $55.07
NBTX analyst ratings
5 analystsNumber of analysts at each rating.
NBTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NBTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$0.54 | −$0.70 | −$0.38 | −$0.50 | −8.2% | 2 |
| Next fiscal year (2027) | −$0.15 | −$0.22 | −$0.08 | −$0.54 | +72.4% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NBTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current fiscal year (2026) | $29.4M | $10.0M | $49.0M | −9.7% | 6 |
| Next fiscal year (2027) | $44.4M | $2.4M | $121.1M | +50.7% | 6 |
NBTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NBTX revenue: reported and forecast
NBTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (2026) | $0.04 | −$0.13 | −$0.13 | −$0.13 | −$0.54 | −1,372.7% | 1 up · 0 down |
| Next fiscal year (2027) | $0.07 | −$0.29 | −$0.29 | −$0.25 | −$0.15 | −320.9% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NBTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NBTX beat in 11 of 12.
What analysts expect from NBTX
5 analysts cover Nanobiotix; their consensus rating is strong buy (4.60 on a 1–5 scale, where 5 is a strong buy). The average price target is $54.03, 153.7% above the latest close of $21.30. Analysts expect earnings of −$0.54 per share for 2026, −8.2% from a year earlier. For 2027 the average estimate is −$0.15 per share on revenue of $44.4 million. Nanobiotix beat the EPS estimate in 11 of the last 12 quarters.
Related: NBTX income statement, NBTX key metrics, NBTX chart. See the NBTX stock overview for the latest quote and news.
NBTX forecast FAQ
What is Nanobiotix's price target?
The average analyst price target for Nanobiotix is $54.03, 153.7% above the latest close of $21.30.
Is Nanobiotix a buy, hold or sell?
Of 5 analysts covering Nanobiotix, 4 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Nanobiotix's EPS forecast?
Analysts forecast −$0.54 per share for 2026 (range −$0.70 to −$0.38); for 2027 the estimate is −$0.15.
What is Nanobiotix's revenue forecast?
The average revenue estimate for 2026 is $29.4 million, growth of −9.7%; for 2027 it is $44.4 million.
Does Nanobiotix usually beat earnings estimates?
Nanobiotix reported EPS at or above the analyst estimate in 11 of the last 12 quarters.